{"id":54635,"date":"2026-01-19T16:49:02","date_gmt":"2026-01-19T08:49:02","guid":{"rendered":"https:\/\/flcube.com\/?p=54635"},"modified":"2026-01-19T16:49:03","modified_gmt":"2026-01-19T08:49:03","slug":"biogens-high-dose-spinraza-wins-eu-approval-for-5q-sma-after-japan-nod","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54635","title":{"rendered":"Biogen&#8217;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod"},"content":{"rendered":"\n<p><strong>Biogen Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ:\u202fBIIB<\/a>) announced that the <strong>European Commission (EC)<\/strong> has granted marketing authorization for a <strong>high\u2011dose regimen of SPINRAZA (nusinersen)<\/strong> for the treatment of <strong>5q spinal muscular atrophy (SMA)<\/strong>, representing approximately <strong>95% of all SMA cases<\/strong>. The approval follows a <strong>Complete Response Letter (CRL)<\/strong> from the <strong>U.S. FDA<\/strong> in September\u202f2025, with a final U.S. decision expected by <strong>April\u202f3\u202f2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Authority<\/strong><\/td><td>European Commission (EU)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SPINRAZA (nusinersen) High\u2011Dose Regimen<\/td><\/tr><tr><td><strong>Dosage Forms<\/strong><\/td><td>50\u202fmg\/5\u202fmL and 28\u202fmg\/5\u202fmL<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>5q spinal muscular atrophy (SMA)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>12\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>U.S. Status<\/strong><\/td><td>CRL received Sep\u202f2025; FDA decision due Apr\u202f3\u202f2026<\/td><\/tr><tr><td><strong>Japan Status<\/strong><\/td><td>High\u2011dose regimen already approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-dosing-regimen\">Drug Profile &amp; Dosing Regimen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Antisense oligonucleotide<\/strong> that increases <strong>SMN protein<\/strong> production by modifying SMN2 pre\u2011mRNA splicing<\/li>\n\n\n\n<li><strong>High\u2011Dose Regimen:<\/strong><\/li>\n\n\n\n<li><strong>Loading Phase:<\/strong> Two <strong>50\u202fmg doses<\/strong> administered <strong>14 days apart<\/strong> (vs. five 12\u202fmg doses over 14+64 days)<\/li>\n\n\n\n<li><strong>Maintenance:<\/strong> <strong>28\u202fmg injections<\/strong> every <strong>4 months<\/strong> (vs. 12\u202fmg every 4 months)<\/li>\n\n\n\n<li><strong>Transition:<\/strong> Patients on 12\u202fmg regimen receive <strong>one 50\u202fmg dose<\/strong> in place of next 12\u202fmg dose, then switch to 28\u202fmg maintenance<\/li>\n\n\n\n<li><strong>Rationale:<\/strong> Higher loading dose aims for <strong>faster motor function improvements<\/strong> and <strong>more durable SMN protein elevation<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-devote-study\">Clinical Evidence \u2013 DEVOTE Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cohort<\/th><th>Population<\/th><th>Primary Endpoint<\/th><th>Result<\/th><th>Comparator<\/th><\/tr><\/thead><tbody><tr><td><strong>Pivotal Cohort<\/strong><\/td><td>Treatment\u2011na\u00efve symptomatic infants (n\u202f=\u202f59)<\/td><td>CHOP\u2011INTEND motor function at 6\u202fmonths<\/td><td><strong>Statistically significant improvement<\/strong> (p\u202f&lt;\u202f0.001) vs. sham<\/td><td>Matched sham group from ENDEAR study<\/td><\/tr><tr><td><strong>Open\u2011Label Cohort<\/strong><\/td><td>Broad age\/SMA types transitioning from 12\u202fmg (n\u202f=\u202f48)<\/td><td>CHOP\u2011INTEND change from baseline<\/td><td><strong>Mean +8.5 points<\/strong> at 6\u202fmonths<\/td><td>Historical low\u2011dose controls<\/td><\/tr><tr><td><strong>Long\u2011Term Extension<\/strong><\/td><td>All DEVOTE participants<\/td><td>Safety &amp; durability<\/td><td><strong>Sustained improvements<\/strong> through 12\u202fmonths<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>All treated patients (N\u202f=\u202f107)<\/td><td>Grade\u202f\u2265\u202f3 TEAEs<\/td><td><strong>18\u202f%<\/strong> (consistent with SMA disease\/nusinersen profile)<\/td><td>No new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> Three\u2011part <strong>Phase\u202f2\/3 DEVOTE<\/strong> study with ongoing long\u2011term extension<\/li>\n\n\n\n<li><strong>Key Finding:<\/strong> High\u2011dose regimen achieved <strong>faster onset of action<\/strong> and <strong>greater magnitude of motor improvement<\/strong> vs. historical low\u2011dose data<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-outlook\">Market Opportunity &amp; Strategic Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global SMA Market<\/strong><\/td><td>$1.85\u202fbillion<\/td><td>$2.1\u202fbillion<\/td><td>$2.35\u202fbillion<\/td><\/tr><tr><td><strong>5q SMA Share<\/strong><\/td><td>95\u202f%<\/td><td>95\u202f%<\/td><td>95\u202f%<\/td><\/tr><tr><td><strong>EU Market Size<\/strong><\/td><td>$420\u202fmillion<\/td><td>$460\u202fmillion<\/td><td>$490\u202fmillion<\/td><\/tr><tr><td><strong>High\u2011Dose SPINRAZA EU Launch<\/strong><\/td><td>Q2\u202f2026<\/td><td>Full rollout<\/td><td>Market penetration<\/td><\/tr><tr><td><strong>Peak EU Market Share<\/strong><\/td><td>\u2013<\/td><td>35\u202f%<\/td><td>42\u202f%<\/td><\/tr><tr><td><strong>Peak EU Revenue<\/strong><\/td><td>\u2013<\/td><td>$161\u202fmillion<\/td><td>$206\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> <strong>15\u201120\u202f%<\/strong> of patients on low\u2011dose SPINRAZA plateau in motor function; high\u2011dose offers <strong>rescue option<\/strong><\/li>\n\n\n\n<li><strong>Pricing:<\/strong> EU high\u2011dose price estimated at <strong>+30\u202f% premium<\/strong> over 12\u202fmg (\u20ac125,000 vs. \u20ac96,000 per loading phase)<\/li>\n\n\n\n<li><strong>Japan Approval:<\/strong> High\u2011dose approved in <strong>2025<\/strong>; reimbursement secured at comparable premium<\/li>\n\n\n\n<li><strong>U.S. Outlook:<\/strong> CRL requested <strong>additional CMC details<\/strong> and <strong>IV administration feasibility data<\/strong>; Biogen resubmission expected <strong>Q1\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Gene therapies (Zolgensma, Evrysdi)<\/strong> dominate new\u2011patient market<\/li>\n\n\n\n<li><strong>High\u2011dose SPINRAZA<\/strong> targets <strong>maintenance population<\/strong> and <strong>non\u2011responders<\/strong> \u2013 complementary positioning<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> High\u2011dose formulation produced at <strong>Biogen\u2019s Solothurn, Switzerland facility<\/strong>; no new capacity required<\/li>\n\n\n\n<li><strong>Patent Extension:<\/strong> High\u2011dose regimen <strong>extends EU patent protection<\/strong> to <strong>2039<\/strong> (vs. 2034 for 12\u202fmg) via <strong>new dosing regimen patent<\/strong><\/li>\n\n\n\n<li><strong>Patient Conversion:<\/strong> Biogen launching <strong>switch program<\/strong> for existing patients; estimated <strong>25\u202f% conversion by 2027<\/strong> , generating <strong>\u20ac80\u202fmillion incremental revenue<\/strong> without new patient acquisition<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> High\u2011dose data may support <strong>similar regimen for BIIB115<\/strong> (next\u2011generation antisense) in development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SPINRAZA high\u2011dose commercial performance, FDA approval timeline, and competitive positioning. Actual results may differ due to regulatory decisions, pricing negotiations, and gene therapy adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54655,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,993,15],"class_list":["post-54635","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-nasdaq-biib","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen&#039;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54635\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen&#039;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod\" \/>\n<meta property=\"og:description\" content=\"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54635\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T08:49:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T08:49:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen&#8217;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod\",\"datePublished\":\"2026-01-19T08:49:02+00:00\",\"dateModified\":\"2026-01-19T08:49:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635\"},\"wordCount\":563,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901.webp\",\"keywords\":[\"Biogen\",\"NASDAQ: BIIB\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54635#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54635\",\"name\":\"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901.webp\",\"datePublished\":\"2026-01-19T08:49:02+00:00\",\"dateModified\":\"2026-01-19T08:49:03+00:00\",\"description\":\"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54635\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54635#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen&#8217;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54635","og_locale":"en_US","og_type":"article","og_title":"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod","og_description":"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.","og_url":"https:\/\/flcube.com\/?p=54635","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T08:49:02+00:00","article_modified_time":"2026-01-19T08:49:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54635#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54635"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen&#8217;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod","datePublished":"2026-01-19T08:49:02+00:00","dateModified":"2026-01-19T08:49:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54635"},"wordCount":563,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54635#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","keywords":["Biogen","NASDAQ: BIIB","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54635#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54635","url":"https:\/\/flcube.com\/?p=54635","name":"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54635#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54635#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","datePublished":"2026-01-19T08:49:02+00:00","dateModified":"2026-01-19T08:49:03+00:00","description":"Biogen Inc. (NASDAQ:\u202fBIIB) announced that the European Commission (EC) has granted marketing authorization for a high\u2011dose regimen of SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), representing approximately 95% of all SMA cases. The approval follows a Complete Response Letter (CRL) from the U.S. FDA in September\u202f2025, with a final U.S. decision expected by April\u202f3\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54635#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54635"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54635#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","width":1080,"height":608,"caption":"Biogen's High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54635#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen&#8217;s High\u2011Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54635"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54635\/revisions"}],"predecessor-version":[{"id":54653,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54635\/revisions\/54653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54655"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}